<DOC>
	<DOCNO>NCT00504192</DOCNO>
	<brief_summary>The role systemic chemotherapy advance biliary tract cancer ( BTC ) know limited although various single-agent combination therapy test . However , possibility palliative chemotherapy induce prolong survival improve quality life advance BTC base several study . A GERCOR study show promising result gemcitabine combination oxaliplatin first line chemotherapy advance BTC . Therefore , phase II trial plan investigate efficacy toxicity combination chemotherapy gemcitabine dose adjust oxaliplatin patient inoperable BTC Korea .</brief_summary>
	<brief_title>A Phase II Study Gemcitabine With Oxaliplatin First Line Chemotherapy Advanced Biliary Tract Cancer</brief_title>
	<detailed_description>Treatment scheme : Gemcitabine 1000 mg/m2/d IV D1 10mg/m2/min Oxaliplatin 85 mg/m2/d IV D2 2 hour infusion Each cycle repeat every 2 week . Repeated cycle treatment give study unless confirm disease progression unacceptable toxicity . Subjects treat least 4 cycle unless documented disease progression , unacceptable adverse event withdrawal consent .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm biliary tract adenocarcinoma 2 . Inoperable disease define : Localized disease portion liver allow possibility complete surgical removal tumor clear resection margin . Presence metastatic lesion Unresectable recurrent tumor curative resection anatomically resectable inoperable associate medical condition 3 . Biliary obstruction control 4 . Minimum life expectancy 12 week . 5 . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) evaluable lesion present image study 6 . Age 18 year 7 . ECOG performance status * 2 . 8 . Adequate organ function evidence follow ; Absolute neutrophil count &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L ; total bilirubin â‰¤3xUNL ; AST and/or ALT &lt; 5x UNL ; Creatinine &lt; 1.5mg/dl creatinine clearance &gt; 50 ml/mins 9 . Consent form sign date prior study specific procedure . 10 . Subject able comply schedule followup management toxicity . 1 . Decompensated Cirrhosis stage C ( Index &gt; 10 ) accord ChildPugh Classification 2 . Prior systemic chemotherapy 3 . Subject reproductive potential ( M/F ) use adequate contraceptive measure . 4 . Pregnancy breastfeed . 5 . Other serious illness medical condition , notably heart lung failure , active uncontrolled infection ( infection require antibiotic ) . 6 . Past concurrent history neoplasm , except curatively treat basal cell skin cancer adequately treat insitu carcinoma cervix . 7 . Symptomatic uncontrolled brain metastasis 8 . Other concomitant anticancer agent , include Tamoxifen Interferon . 9 . Subjects regularly follow psychological , social , familial geographic reason . 10 . Participation another clinical study within 30 day inclusion . 11 . History severe hypersensitivity reaction gemcitabine oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>